Beauty Firms Chase 'Ozempic Face' Market as Weight-Loss Drugs Boom
The companies are testing injectables and new products as clinics report rising demand for procedures that address facial volume loss after rapid weight loss.
- Swiss skincare firm Galderma, Brazilian cosmetics group Natura, and beauty giant L'Oréal are developing treatments for facial sagging and volume loss tied to the boom in obesity drugs.
- The obesity drug market could reach $150 billion in annual sales by 2030, while 53% of aesthetics clinics anticipate an influx of patients due to weight-loss medications.
- Consultant dermatologist Beibei Du-Harpur of King's College London said the term 'Ozempic face' is misleading, as facial volume loss stems from rapid weight loss rather than the drugs themselves.
- Galderma's Anne-Cecile Chevrier said 'sagginess is a concern,' while L'Oréal's Delphine Viguier-Hovasse confirmed the company is testing products on GLP-1 users in separate studies.
- Plastic surgeon Dr. Graeme Glass of British beauty brand LYMA cautioned that creams cannot alter the face's ligamental structure or reach the deep fat layer where volume loss occurs.
10 Articles
10 Articles
The explosion of slimming drugs creates a new market for L’Oréal, Galderma and Natura, which are developing treatments for sagging and volume loss in the face - Experts point out limited effectiveness of cosmetics and need for scientific documentation
Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Swiss skincare firm Galderma , Brazilian cosmetics group Natura and beauty giant L'Oreal are testing treatments for consumers worried about facial sagging and volume loss, looking to capitalise on a growing market tied to the boom in obesity drugs.
Companies seek to reverse the side effects of drugs, such as gastrointestinal problems, skin flaccidity, or changes in smell and taste
Ozempic face sparks beauty industry gold rush
LONDON/PARIS: Swiss skincare firm Galderma, Brazilian cosmetics group Natura and beauty giant L'Oreal are testing treatments for consumers worried about facial sagging and volume loss, looking to capitalise on a growing market tied to the boom in obesity drugs.The companies are targeting concerns known as "Ozempic face," a term that emerged as the diabetes drug became widely associated with weight loss. Experts say the loss of facial volume is l…
The Economic Times
Times of IndiaBeauty firms chase 'Ozempic face' market as weight-loss drugs boom
Galderma, Natura, and L'Oreal are developing treatments for consumers experiencing facial sagging due to rapid weight loss. These companies are responding to increased demand linked to the popularity of GLP-1 obesity drugs. Experts indicate that rapid weight loss may lead to skin laxity and diminished facial volume. While existing treatments show promise, some limitations remain in addressing deeper facial structure issues.
Coverage Details
Bias Distribution
- 45% of the sources are Center, 44% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
